TUG1 and neoplasm: Next, we exploited the LN229 xenograft mouse model to investigate the efficacy of intravenous treatment with TUG1 ASO coupled with a tumor-specific drug delivery system (antiTUG1-DDS) in vivo48 (Fig. 7c).